Aura Biosciences Completes $40 Million Series D Financing

by Ysios Capital

3 months ago
Ysios Capital, Aura Biosciences, Lundbeckfonden, Advent Life Sciences, Arix Bioscience, Chiesi Ventures, Columbus Venture Partners

Aura Biosciences, a leader in the development of novel targeted therapies in ocular oncology, today announced that it closed a $40 million Series D financing. New investor Medicxi led the round, with

Pzifer secures exclusive option to acquire gene therapy company Vivet Therapeutic

by CIMA - Centro de Investigación Médica Aplicada

3 months ago
Vivet Therapeutics, Pfizer, Wilson's disease, Ysios Capital, gene therapy

Pfizer and Vivet to collaborate on development of potential breakthrough therapy for Wilson disease

Pfizer secures exclusive option to acquire gene therapy company vivet therapeutics

by Ysios Capital

3 months ago
Vivet Therapeutics, Pfizer, Wilson disease, Ysios Capital

Vivet Therapeutics (“Vivet”), a privately held gene therapy biotech company dedicated to developing gene therapy treatments for inherited liver disorders with high unmet medical need, and Pfize...

Ysios Capital wins CataloniaBio & HealthTech Biosuccess Award

by CataloniaBio

3 months ago
biomedicina, Ysios Capital, premio

CataloniaBioHT also recognised the career of Antonio Parente. The awards were given out yesterday by Catalan Minister of Health Alba Vergés at the CataloniaBioHT Gala Dinner at the Sant Pau Art Nouve...

Xeltis Closes €45 Million in Oversubscribed Series C Financing to Advance Aortic and Pulmonary Valve Programs. Ysios Capital participates in the round

by Ysios Capital

2 years ago
Xeltis, Ysios Capital, aortic valve, biomaterials

Xeltis, a clinical-stage medical device company pioneering a restorative approach in heart valve therapy, today announced the completion of an oversubscribed €45 million ($52 million) Series C finan...

Vivet Therapeutics raises €37.5 million in Series A financing round to advance novel gene therapies for treating inherited metabolic diseases

by Ysios Capital

Vivet Therapeutics (‘Vivet’), an emerging biotechnology company developing novel gene therapies for rare, inherited metabolic diseases, announced it has raised €37.5 million in a Series A financ...

BioClin Therapeutics, Inc., Raises $30 Million in Series B Financing Led by Sofinnova Ventures and Ysios Capital

by Ysios Capital

2 years ago
Ysios Capital, BioClin Therapeutics, Sofinnova Ventures, HealthCap, Life Science Partners, Tekla, Caixa Capital Risc, BioFund II

The financing was led by new investors Sofinnova Ventures and Ysios Capital, and included existing investors HealthCap, Life Sciences Partners (LSP), and Tekla Capital Management. Since its founding, ...

OxThera raises EUR 32 million to complete development of Oxabact® for treatment of Primary hyperoxaluria

by Ysios Capital

3 years ago
OxThera, Oxabact®, Primary hyperoxaluria, Ysios Capital, kidney deterioration, calcification of soft tissues

Primary hyperoxaluria (PH) is a rare autosomal recessive disorder leading to markedly elevated levels of endogenous oxalate causing kidney deterioration and a gradual calcification of soft tissues. If...

CorWave Raises $17.1 Million in Series B Financing

by Ysios Capital

3 years ago
CorWave, Ysios Capital

CorWave, a medical technology company that develops innovative mechanical circulatory support devices, has announced that it has completed a $17.1 million (€15.5M) Series B financing. Existing share...

Parkinson’s disease: Prexton Therapeutics, participated by Ysios Capital, completes phase 1 clinical trial

by Ysios Capital

3 years ago
Prexton Therapeutics, Ysios Capital, Parkinson’s disease

Study shows mGluR4 positive allosteric modulator is safe and well tolerated at doses well above those that produce robust effects in Parkinson’s disease animal models

CVRx® Secures $113 Million in New Financing

by Ysios Capital

3 years ago
Ysios Capital, CVRx, Barostim Neo

CVRx, Inc., a private medical device company, has secured equity financing totaling $93 million and a new $20 million debt facility. CVRx plans to use the proceeds for the primary purposes of completi...

Minoryx Therapeutics Initiates Phase 1 clinical trial of MIN-102

by Ysios Capital

3 years ago
X-ALD, Minoryx Therapeutics, MIN-102, Ysios Capital

MIN-102 is a differentiated PPAR gamma agonist with a superior profile for central nervous system related diseases. It has shown robust preclinical proof of concept. The aim of the Phase 1 study is to...